Cargando…

The in vitro anti-viral potential of Setarud (IMOD™), a commercial herbal medicine with protective activity against acquired immune deficiency syndrome in clinical trials

OBJECTIVES: Setarud (IMOD™) is a herbal medicine with beneficial effect for patients suffering Human immunodeficiency virus (HIV) infection and has been approved for IV (intra venues) injection. The beneficial effect of IMOD administration for acquired immune deficiency syndrome (AIDS) patient has b...

Descripción completa

Detalles Bibliográficos
Autores principales: Zabihollahi, Rezvan, Namazi, Rahele, Aghasadeghi, Mohammad Reze, Esfahani, Azar Farhang, Sadat, Seyed Mehdi, Modarressi, Mohammad Hossein
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Medknow Publications & Media Pvt Ltd 2012
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3469945/
https://www.ncbi.nlm.nih.gov/pubmed/23087503
http://dx.doi.org/10.4103/0253-7613.99301
_version_ 1782246162951045120
author Zabihollahi, Rezvan
Namazi, Rahele
Aghasadeghi, Mohammad Reze
Esfahani, Azar Farhang
Sadat, Seyed Mehdi
Modarressi, Mohammad Hossein
author_facet Zabihollahi, Rezvan
Namazi, Rahele
Aghasadeghi, Mohammad Reze
Esfahani, Azar Farhang
Sadat, Seyed Mehdi
Modarressi, Mohammad Hossein
author_sort Zabihollahi, Rezvan
collection PubMed
description OBJECTIVES: Setarud (IMOD™) is a herbal medicine with beneficial effect for patients suffering Human immunodeficiency virus (HIV) infection and has been approved for IV (intra venues) injection. The beneficial effect of IMOD administration for acquired immune deficiency syndrome (AIDS) patient has been proved in previous clinical trials. Here the in vitro inhibitory effect of IMOD against HIV-1, Herpes simplex virus (HSV) and murine leukemia viruses (MLV) was evaluated. MATERIALS AND METHODS: HIV single cycle replication and HSV plaque reduction assays were used to evaluate the anti-viral effect. The level of HIV replication was monitored by p24 capture Enzyme-linked immunosorbent assay (ELISA). The single round infection [with green fluorescent protein (GFP) reporter MLV and HIV], virucidal and time-of-additions (HSV) assays were utilized to determine the mode of anti-viral activity. The toxicity of IMOD for cells was monitored by XTT (sodium 3_-[1 (phenylaminocarbonyl)- 3,4-tetrazolium]-bis (4-methoxy-6-nitro)benzene sulfonic acid) cell proliferation assay kit. RESULTS: IMOD inhibited 50% of HIV-1 and HSV replication (IC(50)) at 6.5 × 10(-4) and 4.3 × 10(-3)V/V concentrations, respectively. The IC(50) value against HIV-1 and MLV infection were 6 × 10(-4)V/V and 4.9 × 10(-4)V/V. Virucidal assay showed that IMOD reduces the potency of HIV and HSV particles to 41 and 54% of control, respectively. Time-of-addition study revealed that IMOD inhibits the replication of HSV at a stage after penetration of virions to the target cells. CONCLUSIONS: Data from this study indicate that IMOD has significant anti-viral activity against HIV, HSV and MLV. Setarud could be subjected to further investigation after isolation of the constituents and determination of the toxic components.
format Online
Article
Text
id pubmed-3469945
institution National Center for Biotechnology Information
language English
publishDate 2012
publisher Medknow Publications & Media Pvt Ltd
record_format MEDLINE/PubMed
spelling pubmed-34699452012-10-19 The in vitro anti-viral potential of Setarud (IMOD™), a commercial herbal medicine with protective activity against acquired immune deficiency syndrome in clinical trials Zabihollahi, Rezvan Namazi, Rahele Aghasadeghi, Mohammad Reze Esfahani, Azar Farhang Sadat, Seyed Mehdi Modarressi, Mohammad Hossein Indian J Pharmacol Research Article OBJECTIVES: Setarud (IMOD™) is a herbal medicine with beneficial effect for patients suffering Human immunodeficiency virus (HIV) infection and has been approved for IV (intra venues) injection. The beneficial effect of IMOD administration for acquired immune deficiency syndrome (AIDS) patient has been proved in previous clinical trials. Here the in vitro inhibitory effect of IMOD against HIV-1, Herpes simplex virus (HSV) and murine leukemia viruses (MLV) was evaluated. MATERIALS AND METHODS: HIV single cycle replication and HSV plaque reduction assays were used to evaluate the anti-viral effect. The level of HIV replication was monitored by p24 capture Enzyme-linked immunosorbent assay (ELISA). The single round infection [with green fluorescent protein (GFP) reporter MLV and HIV], virucidal and time-of-additions (HSV) assays were utilized to determine the mode of anti-viral activity. The toxicity of IMOD for cells was monitored by XTT (sodium 3_-[1 (phenylaminocarbonyl)- 3,4-tetrazolium]-bis (4-methoxy-6-nitro)benzene sulfonic acid) cell proliferation assay kit. RESULTS: IMOD inhibited 50% of HIV-1 and HSV replication (IC(50)) at 6.5 × 10(-4) and 4.3 × 10(-3)V/V concentrations, respectively. The IC(50) value against HIV-1 and MLV infection were 6 × 10(-4)V/V and 4.9 × 10(-4)V/V. Virucidal assay showed that IMOD reduces the potency of HIV and HSV particles to 41 and 54% of control, respectively. Time-of-addition study revealed that IMOD inhibits the replication of HSV at a stage after penetration of virions to the target cells. CONCLUSIONS: Data from this study indicate that IMOD has significant anti-viral activity against HIV, HSV and MLV. Setarud could be subjected to further investigation after isolation of the constituents and determination of the toxic components. Medknow Publications & Media Pvt Ltd 2012 /pmc/articles/PMC3469945/ /pubmed/23087503 http://dx.doi.org/10.4103/0253-7613.99301 Text en Copyright: © Indian Journal of Pharmacology http://creativecommons.org/licenses/by-nc-sa/3.0 This is an open-access article distributed under the terms of the Creative Commons Attribution-Noncommercial-Share Alike 3.0 Unported, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
spellingShingle Research Article
Zabihollahi, Rezvan
Namazi, Rahele
Aghasadeghi, Mohammad Reze
Esfahani, Azar Farhang
Sadat, Seyed Mehdi
Modarressi, Mohammad Hossein
The in vitro anti-viral potential of Setarud (IMOD™), a commercial herbal medicine with protective activity against acquired immune deficiency syndrome in clinical trials
title The in vitro anti-viral potential of Setarud (IMOD™), a commercial herbal medicine with protective activity against acquired immune deficiency syndrome in clinical trials
title_full The in vitro anti-viral potential of Setarud (IMOD™), a commercial herbal medicine with protective activity against acquired immune deficiency syndrome in clinical trials
title_fullStr The in vitro anti-viral potential of Setarud (IMOD™), a commercial herbal medicine with protective activity against acquired immune deficiency syndrome in clinical trials
title_full_unstemmed The in vitro anti-viral potential of Setarud (IMOD™), a commercial herbal medicine with protective activity against acquired immune deficiency syndrome in clinical trials
title_short The in vitro anti-viral potential of Setarud (IMOD™), a commercial herbal medicine with protective activity against acquired immune deficiency syndrome in clinical trials
title_sort in vitro anti-viral potential of setarud (imod™), a commercial herbal medicine with protective activity against acquired immune deficiency syndrome in clinical trials
topic Research Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3469945/
https://www.ncbi.nlm.nih.gov/pubmed/23087503
http://dx.doi.org/10.4103/0253-7613.99301
work_keys_str_mv AT zabihollahirezvan theinvitroantiviralpotentialofsetarudimodacommercialherbalmedicinewithprotectiveactivityagainstacquiredimmunedeficiencysyndromeinclinicaltrials
AT namazirahele theinvitroantiviralpotentialofsetarudimodacommercialherbalmedicinewithprotectiveactivityagainstacquiredimmunedeficiencysyndromeinclinicaltrials
AT aghasadeghimohammadreze theinvitroantiviralpotentialofsetarudimodacommercialherbalmedicinewithprotectiveactivityagainstacquiredimmunedeficiencysyndromeinclinicaltrials
AT esfahaniazarfarhang theinvitroantiviralpotentialofsetarudimodacommercialherbalmedicinewithprotectiveactivityagainstacquiredimmunedeficiencysyndromeinclinicaltrials
AT sadatseyedmehdi theinvitroantiviralpotentialofsetarudimodacommercialherbalmedicinewithprotectiveactivityagainstacquiredimmunedeficiencysyndromeinclinicaltrials
AT modarressimohammadhossein theinvitroantiviralpotentialofsetarudimodacommercialherbalmedicinewithprotectiveactivityagainstacquiredimmunedeficiencysyndromeinclinicaltrials
AT zabihollahirezvan invitroantiviralpotentialofsetarudimodacommercialherbalmedicinewithprotectiveactivityagainstacquiredimmunedeficiencysyndromeinclinicaltrials
AT namazirahele invitroantiviralpotentialofsetarudimodacommercialherbalmedicinewithprotectiveactivityagainstacquiredimmunedeficiencysyndromeinclinicaltrials
AT aghasadeghimohammadreze invitroantiviralpotentialofsetarudimodacommercialherbalmedicinewithprotectiveactivityagainstacquiredimmunedeficiencysyndromeinclinicaltrials
AT esfahaniazarfarhang invitroantiviralpotentialofsetarudimodacommercialherbalmedicinewithprotectiveactivityagainstacquiredimmunedeficiencysyndromeinclinicaltrials
AT sadatseyedmehdi invitroantiviralpotentialofsetarudimodacommercialherbalmedicinewithprotectiveactivityagainstacquiredimmunedeficiencysyndromeinclinicaltrials
AT modarressimohammadhossein invitroantiviralpotentialofsetarudimodacommercialherbalmedicinewithprotectiveactivityagainstacquiredimmunedeficiencysyndromeinclinicaltrials